Art. -Nr.: HY-N0629

Maslinic acid

(Synonyms: Crategolic acid; 2α-Hydroxyoleanolic acid)

17 Cited Publications

Kundenbewertung

Based on 17 publication(s) in Google Scholar

Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.87%
CAS. Nr.: 4373-41-5
Formel: C₃₀H₄₈O₄
Molecular Weight:472.70

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Maslinic acid Chemical Structure

CAS. Nr.: 4373-41-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (17)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Maslinic acid can inhibit the DNA-binding activity of NF-κB p65 and abolish the phosphorylation of IκB-α, which is required for p65 activation.

IC₅₀ & Target^[1]

p65

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle HIV Isoform-spezifische Produkte anzeigen :

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
518A2	EC₅₀	13.7 μM Compound: 3; MA	Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
518A2	EC₅₀	13.7 μM Compound: 6	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 28033541]
518A2	EC₅₀	13.7 μM Compound: MA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
518A2	EC₅₀	13.7 μM Compound: MA	Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 518A2 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
518A2	EC₅₀	13.7 μM Compound: MA	Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human 518A2 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
518A2	IC₅₀	13.7 μM Compound: 1	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24161703]
518A2	IC₅₀	13.7 μM Compound: MA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24361521]
518A2	IC₅₀	13.7 μM Compound: MA	Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay Cytotoxicity against human 518A2 cells after 96 hrs by SRB assay	[PMID: 24440377]
8505C	EC₅₀	17 μM Compound: 6	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 28033541]
8505C	EC₅₀	17 μM Compound: MA	Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human 8505C cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
8505C	EC₅₀	17 μM Compound: MA	Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human 8505C cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
8505C	IC₅₀	17 μM Compound: 1	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24161703]
8505C	IC₅₀	17 μM Compound: MA	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24361521]
8505C	IC₅₀	17 μM Compound: MA	Cytotoxicity against human 8505C cells after 96 hrs by SRB assay Cytotoxicity against human 8505C cells after 96 hrs by SRB assay	[PMID: 24440377]
A2780	EC₅₀	19.5 μM Compound: 3; MA	Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
A2780	EC₅₀	19.5 μM Compound: 6	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 28033541]
A2780	EC₅₀	19.5 μM Compound: MA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
A2780	EC₅₀	19.5 μM Compound: MA	Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A2780 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A2780	EC₅₀	19.5 μM Compound: MA	Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human A2780 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
A2780	IC₅₀	19.5 μM Compound: 1	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24161703]
A2780	IC₅₀	19.5 μM Compound: MA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24361521]
A2780	IC₅₀	19.5 μM Compound: MA	Cytotoxicity against human A2780 cells after 96 hrs by SRB assay Cytotoxicity against human A2780 cells after 96 hrs by SRB assay	[PMID: 24440377]
A549	EC₅₀	23.4 μM Compound: 3; MA	Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
A549	EC₅₀	23.4 μM Compound: 6	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 28033541]
A549	EC₅₀	23.4 μM Compound: MA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
A549	EC₅₀	23.4 μM Compound: MA	Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human A549 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
A549	EC₅₀	23.4 μM Compound: MA	Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human A549 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
A549	IC₅₀	23.4 μM Compound: 1	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24161703]
A549	IC₅₀	23.4 μM Compound: MA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24361521]
A549	IC₅₀	23.4 μM Compound: MA	Cytotoxicity against human A549 cells after 96 hrs by SRB assay Cytotoxicity against human A549 cells after 96 hrs by SRB assay	[PMID: 24440377]
B16-F10	IC₅₀	>10 μM Compound: I; MA	Cytotoxicity against mouse B16-F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33956447]
B16-F10	IC₅₀	36.2 μM Compound: 2, MA, Maslinic acid	Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 24480359]
B16-F10	IC₅₀	36.2 μM Compound: II, Maslinic acid	Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay Growth inhibition of mouse B16F10 cells after 72 hrs by MTT assay	[PMID: 29471121]
B16-F10	IC₅₀	36.2 μM Compound: II; MA; Maslinic acid	Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against mouse B16F10 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
B16-F10	IC₅₀	36.2 μM Compound: MA	Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
BV-2	IC₅₀	17.8 μM Compound: 5	Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay Anti-inflammatory in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production pre-incubated before LPS challenge for 24 hrs by Griess reagent based assay	[PMID: 28358502]
FaDu	EC₅₀	17 μM Compound: MA	Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human FADU cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
HepG2	IC₅₀	>10 μM Compound: 17	Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells after 72 hrs by MTT assay	[PMID: 27797185]
HepG2	IC₅₀	>10 μM Compound: I; MA	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33956447]
HepG2	IC₅₀	>100 μM Compound: 12	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
HepG2	IC₅₀	99.2 μM Compound: II, Maslinic acid	Growth inhibition of human HepG2 cells after 72 hrs by MTT assay Growth inhibition of human HepG2 cells after 72 hrs by MTT assay	[PMID: 29471121]
HepG2	IC₅₀	99.2 μM Compound: II; MA; Maslinic acid	Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
HepG2	IC₅₀	99.2 μM Compound: MA	Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
HSC-T6	EC₅₀	17.3 nM Compound: 205	Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay Antiproliferative activity against rat HSC-T6 cells assessed as reduction in cell proliferation measured after 48 hrs by MTT assay	[PMID: 29353722]
HT-29	EC₅₀	28.8 μM Compound: 3; MA	Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
HT-29	EC₅₀	28.8 μM Compound: 6	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 28033541]
HT-29	EC₅₀	28.8 μM Compound: MA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
HT-29	EC₅₀	28.8 μM Compound: MA	Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human HT-29 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
HT-29	EC₅₀	28.8 μM Compound: MA	Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human HT-29 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
HT-29	IC₅₀	>10 μM Compound: I; MA	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33956447]
HT-29	IC₅₀	28.8 μM Compound: 1	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24161703]
HT-29	IC₅₀	28.8 μM Compound: MA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24361521]
HT-29	IC₅₀	28.8 μM Compound: MA	Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay Cytotoxicity against human HT-29 cells after 96 hrs by SRB assay	[PMID: 24440377]
HT-29	IC₅₀	32.2 μM Compound: II, Maslinic acid	Growth inhibition of human HT-29 cells after 72 hrs by MTT assay Growth inhibition of human HT-29 cells after 72 hrs by MTT assay	[PMID: 29471121]
HT-29	IC₅₀	32.2 μM Compound: II; MA; Maslinic acid	Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as growth inhibition after 72 hrs by MTT assay	[PMID: 27128174]
HT-29	IC₅₀	32.2 μM Compound: MA	Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 36542806]
KB	ED₅₀	51.5 μM Compound: 5	Cytotoxicity against human KB cells by SRB assay Cytotoxicity against human KB cells by SRB assay	[PMID: 16562832]
KB	IC₅₀	>100 μM Compound: 12	Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human KB cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
Lu1	IC₅₀	>100 μM Compound: 12	Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human Lu1 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	EC₅₀	>30 μM Compound: 6	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 28033541]
MCF7	EC₅₀	>30 μM Compound: MA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
MCF7	EC₅₀	24.4 μM Compound: MA	Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay Anticancer activity against human MCF7 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
MCF7	EC₅₀	37.2 μM Compound: 3; MA	Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against human MCF7 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
MCF7	EC₅₀	37.2 μM Compound: MA	Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against human MCF7 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
MCF7	IC₅₀	>10 μM Compound: 17	Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay Cytotoxicity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27797185]
MCF7	IC₅₀	>100 μM Compound: 12	Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay Cytotoxicity against human MCF7 cells assessed as growth inhibition after 72 hrs by neutral red assay	[PMID: 28318944]
MCF7	IC₅₀	16.6 μM Compound: MA	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24361521]
MCF7	IC₅₀	24.4 μM Compound: 1	Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay Cytotoxicity against human MCF7 cells after 96 hrs by SRB assay	[PMID: 24161703]
MDCK	CC₅₀	23.3 μM Compound: Maslinic acid	Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs Cytotoxicity against MDCK cells assessed as decrease in cell viability after 72 hrs	[PMID: 29394063]
NCI-N87	IC₅₀	>10 μM Compound: 17	Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay Cytotoxicity against human NCI-N87 cells after 72 hrs by MTT assay	[PMID: 27797185]
NIH3T3	EC₅₀	16.6 μM Compound: MA	Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells measured after 96 hrs by sulforhodamine B assay	[PMID: 31330447]
NIH3T3	EC₅₀	21.1 μM Compound: 3; MA	Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells assessed as reduction in cell proliferation after 96 hrs by sulforhodamine B assay	[PMID: 27149037]
NIH3T3	EC₅₀	21.1 μM Compound: 6	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 28033541]
NIH3T3	EC₅₀	21.1 μM Compound: MA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine-B assay	[PMID: 29529499]
NIH3T3	EC₅₀	21.1 μM Compound: MA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by sulforhodamine B assay	[PMID: 30278332]
NIH3T3	IC₅₀	16.6 μM Compound: 1	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24161703]
NIH3T3	IC₅₀	16.6 μM Compound: MA	Cytotoxic activity against mouse NIH/3T3 cells by SRB assay Cytotoxic activity against mouse NIH/3T3 cells by SRB assay	[PMID: 26383128]
NIH3T3	IC₅₀	21.1 μM Compound: MA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24440377]
NIH3T3	IC₅₀	21.4 μM Compound: MA	Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay Cytotoxicity against mouse NIH/3T3 cells after 96 hrs by SRB assay	[PMID: 24361521]
Sf21	IC₅₀	>40 μM Compound: 11	Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis Inhibition of human recombinant COX2 expressed in baculovirus infected sf21 cells assessed as decrease in PGE2 formation using arachidonic acid as substrate preincubated for 10 mins followed by substrate addition measured after 45 mins by LC-MS analysis	[PMID: 31774676]

In Vitro

Maslinic acid (MA) inhibits LPS-induced NF-κB translocation to nucleus and phosphorylation of IκB-α. Maslinic acid has also been reported to suppress NF-κB regulated osteoclastogenesis in bone marrow monocytes and inhibit TNF-α-induced NF-κB activity and its downstream genes’ expression in pancreatic cancer cells. To confirm if the anti-inflammatory effects of olive pomace extracts (OPEs) inRAW264.7 cells can be attributed to Maslinic acid, dose-dependence experiments determined the effective concentration of Maslinic acid to be 10-20 μM. 20 μM Maslinic acid significantly suppresses TNF-α production and inhibits IL-1, IL-6, and COX-2 mRNA expression in RAW 264.7 cell. Maslinic acid (at 10 and 20 μM) significantly suppresses the DNA-binding activity of NF-κB p65 in LPS-induced RAW 264.7 cells. Pretreatment with Maslinic acid significantly reduces the LPS-induced phosphorylation of IκB-α^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Paw swelling is alleviated when mice are administered with 200 mg/kg Maslinic acid (MA), significantly suppressing inflammation, compared to the carrageenan induced control group, 4 h after λ-carrageenan injection (0.91±0.51 mm and 1.79±0.4 mm, respectively)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 4373-41-5
Appearance Solid
Molecular Weight 472.70
Formel C₃₀H₄₈O₄
Color White to off-white
SMILES

C[C@]([C@@]1([H])[C@]2(C[C@@H](O)[C@@H]3O)C)(CC[C@@]2([H])C3(C)C)[C@@](C4=CC1)(CC[C@]5(C(O)=O)[C@@]4([H])CC(C)(C)CC5)C
Synonyms

Crategolic acid; 2α-Hydroxyoleanolic acid
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (17)

All WBRT-PCRIn Vivo Efficacy StudyHistological Imaging/Staining

Sort by:

Journal Impact Factor

Cancer Lett

Galactosyltransferase B4GALT1 confers chemoresistance in pancreatic ductal adenocarcinomas by upregulating N-linked glycosylation of CDK11p110. [Abstract]

2021 Mar 1:500:228-243. PMID: 33309857

Maslinic acid purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2021 Mar 1:500:228-243. [Abstract]

Western blot analysis of GemR DT6066/MiaPaca2 cells treated with Maslinic acid (20 μM; 12 h) (NF-κB inhibitor) or placebo. The results showed that depletion of p65 by an inhibitor, Maslinic acid, significantly reduced p65 phosphorylation and its downstream B4GALT1 expression at protein levels in both mouse and human gemcitabine-resistant cells.

Maslinic acid purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2021 Mar 1:500:228-243. [Abstract]

RT-PCR analysis of B4GALT1 mRNA expression in the GemR DT6066/MiaPaca2 cells treated with Maslinic acid (20 μM; 12 h) (NF-κB inhibitor) or placebo. The results showed that depletion of p65 by an inhibitor, Maslinic acid, significantly downregulated B4GALT1 expression at mRNA levels in both mouse and human gemcitabine-resistant cells.
Acta Pharmacol Sin

Sonic Hedgehog-Gli1 signaling promotes microglial activation via the IKKβ/NF-κB pathway. [Abstract]

2026 Mar 11. PMID: 41813972
Am J Chin Med

Maslinic Acid Ameliorates Myocardial Ischemia Reperfusion Injury-Induced Oxidative Stress via Activating Nrf2 and Inhibiting NF-[Formula: see text]B Pathways. [Abstract]

2023;51(4):929-951. PMID: 36974993
Cell Rep

Polo-like kinase 2 promotes microglial activation via regulation of the HSP90α/IKKβ pathway. [Abstract]

2024 Oct 8;43(10):114827. PMID: 39383034
PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Cell Oncol (Dordr)

IRAK2-NF-κB signaling promotes glycolysis-dependent tumor growth in pancreatic cancer. [Abstract]

2022 Jun;45(3):367-379. PMID: 35486320

Maslinic acid purchased from MedChemExpress. Usage Cited in: Cell Oncol (Dordr). 2022 Jun;45(3):367-379. [Abstract]

WB analysis of phosphorylated and total NF-κB in IRAK2OE cells treated with 20 µM Maslinic acid (MA) for different times (0, 1, 2, 6, 12 and 24 h). Phosphorylated NF-κB was estimated by normalizing the band intensity of p-NF-κB against that of total NF-κB. The ratios below indicate the relative activity of treated cells compared with that of untreated cells from three independent experiments. The results showed that the level of phosphorylated NF-κB decreased in a time-dependent manner after treatment with MA.
Front Cell Dev Biol

Licarin-B Exhibits Activity Against the Toxoplasma gondii RH Strain by Damaging Mitochondria and Activating Autophagy. [Abstract]

2021 Jun 11:9:684393. PMID: 34179016
Fish Shellfish Immunol

The role of largemouth bass NF-κB/p65: Inhibition of LMBV and activator of IL-18 promoter. [Abstract]

2025 Mar:158:110120. PMID: 39832538

Maslinic acid purchased from MedChemExpress. Usage Cited in: Fish Shellfish Immunol. 2025 Mar:158:110120. [Abstract]

Maslinic acid (MA, 80 mg/L; 100 μL; i.p.) efficiently suppressed the transcription of Msp65. The mRNA levels of Msp65 were analyzed in the liver and spleen using qRT-PCR at different time points (6, 12, 24, 36, 48, 60 and 72 h post injection) after intraperitoneal injection with 80 mg/L MA.

Maslinic acid purchased from MedChemExpress. Usage Cited in: Fish Shellfish Immunol. 2025 Mar:158:110120. [Abstract]

Survival curves of largemouth bass injected with different doses of Maslinic acid (MA, 5-640 mg/L; 100 μL; i.p.).

Maslinic acid purchased from MedChemExpress. Usage Cited in: Fish Shellfish Immunol. 2025 Mar:158:110120. [Abstract]

Histological morphologies in the liver and spleen under Maslinic acid (MA, 80 mg/L; 100 μL; i.p.) treatment. Histological analysis revealed no pathological changes in the liver and spleen tissues of largemouth bass treated with 80 mg/L MA. Scale bars represented 50 μm.
J Cosmet Dermatol

Maslinic acid attenuates UVB-induced oxidative damage in HFF-1 cells. [Abstract]

2023 Aug;22(8):2352-2360. PMID: 36943873
Front Cardiovasc Med

Maslinic Acid Attenuates Ischemia/Reperfusion Injury-Induced Myocardial Inflammation and Apoptosis by Regulating HMGB1-TLR4 Axis. [Abstract]

2021 Nov 10;8:768947. PMID: 34859077
Fitoterapia

Natural product PROTACylation: Development of Maslinic acid-based JAK2 degraders for cancer therapy. [Abstract]

2026 Apr:190:107201. PMID: 41876032
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
DNA Cell Biol

Maslinic Acid Inhibits Myocardial Ischemia-Reperfusion Injury-Induced Apoptosis and Necroptosis via Promoting Autophagic Flux. [Abstract]

2022 May;41(5):487-497. PMID: 35475713
Biochem Biophys Res Commun

Protection by maslinic acid against cisplatin-induced ototoxicity: rescue of ferroptosis by targeting the SLC7A11-GSH-GPX4 pathway. [Abstract]

2026 Apr 16:809:153480. PMID: 41722247
Int J Ophthalmol

Ragweed pollen induces allergic conjunctivitis immune tolerance in mice via regulation of the NF-κB signal pathway. [Abstract]

2021 Jul 18;14(7):955-964. PMID: 34282378
bioRxiv

2024 Jul 25.
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 100 mg/mL (211.55 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.1155 mL

10.5775 mL

21.1551 mL

5 mM

0.4231 mL

2.1155 mL

4.2310 mL

10 mM

0.2116 mL

1.0578 mL

2.1155 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (5.29 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (5.29 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

Cell Assay^[1]

RAW 264.7 cells are seeded in 96-well culture plates at a density of 1×10⁵ cells/mL and after incubation for 24 h, are treated with OPE1 (300 μg/mL or 400 μg/mL), OPE2 (20 μg/mL or 40 μg/mL), or Maslinic acid (10 μM or 20 μM) , as well as with/without LPS at the same time. Cell viability i determined using the WST-1 reagent. Briefly, WST-1 reagent (10 μL) is added to each well and incubated for 1h in a humidified incubator. The absorbance of the samples measured at 450 nm (reference wavelength is 750 nm). Viability is expressed as a percentage of the absorbance measured in LPS-treated cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Five-week-old male Balb/c mice (19-21 g) are housed in a conventional condition and provided with the free access to standard rodent chow and water. Edema is induced by intraplantar injection of 100 μL 1% carrageenan into the hind left paw. Maslinic acid is tested initially at a dose of 200 mg/kg, orally administered 60 min before and after carrageenan injection. Paw thickness is measured using electronic digital calipers, 2, 3, and 4 h following carrageenan treatment. Mice are sacrificed by carbon dioxide inhalation 4 h after carrageenan injection^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Fukumitsu S, et al. Anti-inflammatory and anti-arthritic effects of pentacyclic triterpenoids maslinic acid through NF-κB inactivation. Mol Nutr Food Res. 2016 Feb;60(2):399-409. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.1155 mL	10.5775 mL	21.1551 mL	52.8877 mL
	5 mM	0.4231 mL	2.1155 mL	4.2310 mL	10.5775 mL
	10 mM	0.2116 mL	1.0578 mL	2.1155 mL	5.2888 mL
	15 mM	0.1410 mL	0.7052 mL	1.4103 mL	3.5258 mL
	20 mM	0.1058 mL	0.5289 mL	1.0578 mL	2.6444 mL
	25 mM	0.0846 mL	0.4231 mL	0.8462 mL	2.1155 mL
	30 mM	0.0705 mL	0.3526 mL	0.7052 mL	1.7629 mL
	40 mM	0.0529 mL	0.2644 mL	0.5289 mL	1.3222 mL
	50 mM	0.0423 mL	0.2116 mL	0.4231 mL	1.0578 mL
	60 mM	0.0353 mL	0.1763 mL	0.3526 mL	0.8815 mL
	80 mM	0.0264 mL	0.1322 mL	0.2644 mL	0.6611 mL
	100 mM	0.0212 mL	0.1058 mL	0.2116 mL	0.5289 mL

Keywords

Maslinic acid

17 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Maslinic acid

Anti-Infection Compound Library

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Antiviral Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Anti-diabetic Compound Library

Lipid Compound Library

Oxygen Sensing Compound Library

Antibacterial Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Food-Sourced Compound Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Antiviral Traditional Chinese Medicine Active Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Highly Selective Inhibitors Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Fatty Acids Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Tibetan Medicine Compound Library

PBCRBS Traditional Chinese Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Mass Spectrometry Human Metabolite Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Mongolian Medicine Compound Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

RNA Binding Bioactive Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Maslinic acid

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle HIV Isoform-spezifische Produkte anzeigen

Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (17)

Lösungsmittel & Löslichkeit

Protokoll

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Maslinic acid Related Classifications